摘要
目的探讨沙格雷酯对2型糖尿病(T2DM)合并不稳定型心绞痛(UA)的疗效。方法选择医院收治的T2DM合并UA患者136例,随机分为对照组和观察组,各68例。两组患者均给予调脂、扩血管、降糖等基础治疗,并口服肠溶阿司匹林;对照组在此基础上给予氯吡格雷,观察组给予沙格雷酯,疗程均为6个月。结果治疗后,观察组的临床疗效总有效率为95.59%,显著高于对照组的88.24%(P<0.05);观察组心电图改善总有效率为95.59%,与对照组的92.65%相当(P>0.05);两组患者左心室舒张末内径(LVEDd)、左心室射血分数(LVEF)均有显著改善(P<0.05),但组间比较,差异无统计学意义(P>0.05);两组患者超敏C反应蛋白(hs-CRP)、D-二聚体、纤维蛋白原(FIB)均较治疗前显著改善,且观察组改善程度大于对照组(P<0.05)。两组患者心肌酶血清肌酸激酶同工酶(CK-MB)和心肌肌钙蛋白(c Tn I)治疗前后均无显著变化(P>0.05)。两组患者在治疗期间及治疗后均无明显不良反应发生。结论沙格雷酯治疗T2DM合并UA患者疗效佳,能显著改善患者的临床症状,值得临床推广。
Objective To investigate the efficacy of sarpogrelate in treating type 2 diabetes mellitus( T2DM) complicated with unstable angina( UA).Methods 136 cases of patients with T2 DM and UA were randomly divided into the control and the observation groups,68 cases in each group.Both groups were given lipid,blood,blood sugar and other basic treatment and oral enteric aspirin; on this basis,the control group was given clopidogrel,and on the basis of the control group,the observation group was given sarpogrelate.Both groups were treated for 6 months.Results After treatment,the total clinical effective rate of the observation group was 95.59%,which was significantly higher than 88.24% of the control group( P < 0.05); the total effective rate of electrocardiogram improvement of the observation group was 95.59%,which had no statistically significant difference with 92.65% of the control group( P > 0.05).After treatment,the two groups of patients LVEF,LVEDd were significantly improved,and the difference was statistically significant( P <0.05); the difference was not statistically significant( between groups P > 0.05); the LVEF,LVEDd of the two groups were significantly improved( P < 0.05) and the difference between the two groups was not statistically significant( P > 0.05); the Hs- CRP,D- D and FIB of the two groups improved significantly,and the degree of improvement in the observation group was more than the control group( P < 0.05); the CK- MB and CTn I of the two groups showed no significant changes( P > 0.05).During and after treatmentm the two groups showed no significant adverse effects.Conclusion Sarpogrelate in treating T2 DM patients complicated with UA has good efficacy,can significantly improve the patient's clinical symptoms,which is worthy of clinical promotion.
出处
《中国药业》
CAS
2015年第24期74-76,共3页
China Pharmaceuticals